Drug Trial Radar · NCT00004128
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Dec 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Sep 1999
Primary completion
Jan 2008
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood or bone marrow and stored. More chemotherapy or radiation therapy is given prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. Interleukin-2 may stimulate the patient's white blood cells to kill cancer cells. PURPOSE: This randomized phase III trial is studying two different regimens of combination chemotherapy, interleukin-2, and peripheral stem cell transplant and comparing them to see how well they work in treating patients with acute myeloid leukemia.
Conditions
- Leukemia
Interventions
aldesleukinBiological
filgrastimBiological
busulfanDrug
cyclophosphamideDrug
cytarabineDrug
daunorubicin hydrochlorideDrug
etoposideDrug
autologous bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of overall survival and disease-free survival after first randomization
- Duration of overall survival and disease-free survival after second randomization
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.